BlinkLab Limited focuses on the development and commercialization of intellectual property related to smartphone-neurobehavioral testing. The company's smartphone-based application serves as a medical device to perform neurometric tests, such as eyeblink conditioning, prepulse inhibition of acoustic startle, and habituation of eye blink response that serve as biomarkers for neurological and psychiatric disorders. Its application records and uploads the neurometric test results to an online platform, where the data is analyzed using machine learning to aid in the diagnosis of autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), schizophrenia, and other neurodevelopmental conditions. The company was incorporated in 2021 and is based in Sydney, Australia.